CANbridge Pharmaceuticals Inc. announced that the core part of the ongoing CAN103 Phase 2 trial, in treatment-naïve patients aged 12 or above with Gaucher disease Types I and III, has reached full enrollment.
CANbridge Pharmaceuticals Inc. announced that the core part of the ongoing CAN103 Phase 2 trial, in treatment-naïve patients aged 12 or above with Gaucher disease Types I and III, has reached full enrollment.